$CMPR

Cimpress (NASDAQ:CMPR) Reaches New 52

Cimpress plc (NASDAQ:CMPR) hit a new 52-week high on Tuesday, trading up to $105.00 and last at $104.94 versus a prior close of $102.39. The article also cites recent analyst actions: Zacks downgraded to “hold,” while Truist set a $110 target and Barrington raised its to $113. On April 29, Cimpress reported Q1 EPS of $0.55 and revenue of $886.21M.

Original reporting
Published May 29, 2026, 1:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 29, 2026, 2:20 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Cimpress (NASDAQ:CMPR) Reaches New 52 — source image
Decision brief

The 30-second read

$CMPRNeutralMed
01

Why it matters

CMPR’s new 52-week high suggests improving near-term sentiment, while the downgrade-to-hold and insider selling can cap upside and increase two-sided trading around the next earnings/updates.

02

Market read

Best used as a momentum/positioning input for CMPR rather than a standalone fundamental catalyst.

03

What to watch

The article bundles multiple analyst actions without detailing changes in underlying assumptions; traders may over-weight the price print versus fundamentals.

Relevance 8/10Novelty 6/10Timing: During Tuesday’s session after CMPR printed a new 52-week high.

Background

The article summarizes CMPR’s Tuesday trading range, recent analyst rating/target changes, the last reported quarter’s EPS/revenue vs consensus, and an EVP share sale disclosed via SEC filing.

Company-level read

Ticker impact

$CMPRNeutralMedium confidence
Context

Cimpress shares hit a new 52-week high and the article also cites recent analyst rating/target changes plus an insider Form 4 sale.

Expected impact

Choppy upside bias: likely follow-through attempts near resistance, but expect volatility around analyst/insider headlines.

Evidence & confidence

The piece provides a concrete price move (52-week high), multiple rating/target updates, and an executive sale; however it does not introduce a new fundamental catalyst beyond the already-referenced earnings date.

Market effects

Limited read-across; mass customization/web-to-print peers are not specifically mentioned with new guidance.

None stated.

None stated.

Counterpoint

The breakout may be sentiment-driven around analyst target chatter rather than a fresh operating catalyst, so mean reversion risk remains high.

Key entities

  • Cimpress plc

    CMPR stock reached a new 52-week high; article cites analyst rating/target changes and an EVP insider sale.

Related articles

$CMPRLow

CIMPRESS plc (CMPR): Results of Operations and Financial Condition

CIMPRESS plc (CMPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. cmpr-20260729 0001262976 false 0001262976 2024-10-30 2024-10-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________ Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date o

$SMCIMed

Super Micro Computer Landed $60 Billion in Orders Last Quarter, but Trades at Just $30

Super Micro Computer (SMCI) said it booked over $60B in new orders in its fiscal Q4 ended June 30, lifting backlog to a record. It guided FY2026 revenue near the low end of $11B to $12.5B and gross margins at 15% to 17%. The company also plans $7B equity financing for AI server orders, noting some orders may not be firm and citing an independent review tied to export control issues.

$CSCOMed

Cisco Stock Is Finally Pricing In A New Growth Story

Cisco raised full-year revenue and EPS guidance on May 13, 2026, citing AI infrastructure demand. Management expects about $9 billion in FY2026 AI orders from hyperscalers and cited 5 hyperscaler design wins in Q3. Cisco shares rose about 20% since, with product orders up 19% YoY excluding hyperscaler growth. Options imply 41% IV ahead of the next catalyst.

$RMDMed

Off Into Weekend, As Early Work Undone

ResMed (ASX:RMD) fell 8.29% on Friday and is 3.09% lower for the week after a strong run. The company reported a solid Q4, with FY26 revenue up 10% to $5.7b, gross Q4 margin 62.3%, FY EPS up 17% to $11.17, and a 10% dividend increase to $0.66. Morgan Stanley downgraded to Equal Weight and cut its price target, citing cooling growth and Philips’ potential US return in 2027.